(NYSE: RCUS) Arcus Biosciences's forecast annual revenue growth rate of -0.11% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.89%.
Arcus Biosciences's revenue in 2026 is $117,000,000.On average, 14 Wall Street analysts forecast RCUS's revenue for 2026 to be $10,094,990,049, with the lowest RCUS revenue forecast at $7,237,629,092, and the highest RCUS revenue forecast at $14,439,604,838. On average, 14 Wall Street analysts forecast RCUS's revenue for 2027 to be $6,619,043,551, with the lowest RCUS revenue forecast at $0, and the highest RCUS revenue forecast at $18,985,406,362.
In 2028, RCUS is forecast to generate $17,369,545,820 in revenue, with the lowest revenue forecast at $8,411,897,485 and the highest revenue forecast at $33,947,078,042.